Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
181 articles about Clearside Biomedical, Inc.
-
Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020
2/26/2020
ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will present at two upcoming investor conferences in March 2020: Cowen 40th Annual Health Care Conference Company Presentation: Wednesday, March 4, 2020 at 8:00 am ET Boston, MA 32nd Annual ROTH Conference P
-
Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings
2/25/2020
Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector™ targeting the suprachoroidal space were given this month at the 17th Annual Angiogenesis Meeting and 43rd Annual Macula Society Meeting.
-
Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society Conferences
2/5/2020
Presentations to Focus on Novel Suprachoroidal Delivery of CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration
-
Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 16, 2020 at 11:30 a.m. PT.
-
Clearside Biomedical to Present at the Stifel 2019 Healthcare Conference
11/13/2019
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will present a company overview at the Stifel 2019 Healthcare Conference in New York, NY on Wednesday, November 20, 2019 at 9:10 a.m. ET.
-
Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update
11/6/2019
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the third quarter of 2019 and provided a corporate update.
-
Clearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 2019
10/30/2019
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that its third quarter 2019 financial results will be reported on Wednesday, November 6, 2019 after the close of the financial markets.
-
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery
10/30/2019
Clearside Biomedical, Inc. announced that REGENXBIO Inc. has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector™ for the delivery of adeno-associated virus -based therapeutics
-
Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
10/23/2019
NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020
-
There are several scheduled PDFUA dates for the U.S. Food and Drug Administration over the next two weeks. Here’s a look.
-
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
9/4/2019
REGENXBIO Inc. and Clearside Biomedical, Inc. announced an option and license agreement for exclusive worldwide rights to Clearside's proprietary, in-office SCS Microinjector™ for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, diabetic retinopathy and other conditions for which anti-vascular endothelial growth factor treatment is currently the standard of care.
-
Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery
7/9/2019
Clearside Biomedical, Inc. announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.
-
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
2/14/2019
Clearside Biomedical, Inc. announced that multiple oral presentations will be given at the 42nd Annual Macula Society Meeting being held February 13-16, 2019 in Bonita Springs, Florida.
-
Clearside Biomedical Shares Plunge as Phase III Xipere Failure Forces the Company to Discontinue ...
11/5/2018
Clearside CEO says the company will discontinue two studies that pair Xipere with Eylea following the Phase III failure. -
Clearside Biomedical’s Phase I/II Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting
11/13/2017
The trial findings presented by Dr. Wykoff at AAO 2017 showed a visual benefit for patients receiving CLS-TA, with a greater benefit in treatment naïve eyes.
-
Clearside Biomedical Announces Third Quarter 2017 Financial Results and Provides Corporate Update
11/8/2017
Clearside’s research and development expenses for the three months ended September 30, 2017 were $16.1 million, compared to $3.7 million for the third quarter of 2016.
-
Clearside Biomedical to Report Third Quarter 2017 Financial Results on November 8, 2017 -- Conference Call to Follow
11/1/2017
Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results following the release.
-
Clearside Biomedical Announces Completion of Patient Enrollment in Phase II Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema
10/25/2017
The trial has enrolled 71 patients who are naïve to pharmacologic treatment for DME.
-
Clearside Biomedical Announces Second Quarter 2017 Financial Results And Provides Corporate Update
8/9/2017
-
Clearside Biomedical Announces Changes To Its Board Of Directors
8/8/2017